patients

Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH CirrhosisMadrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL…

6 days ago
Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell TherapyAnnual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy

Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy

May 06, 2025 14:06 ET  | Source: NMDP MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDPSM hosted its annual gala…

1 week ago
New Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal CancerNew Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

New Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m.…

2 weeks ago
New Study Shows Castle Biosciences DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node PositivityNew Study Shows Castle Biosciences DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

New Study Shows Castle Biosciences DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National…

2 weeks ago
Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPHThree-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the results of long-term data demonstrating…

3 weeks ago
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

April 26, 2025 10:00 ET  | Source: Protara Therapeutics TARA-002 demonstrates 100% complete response rate at any time and 67%…

3 weeks ago
New Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant MetastasisNew Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

New Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests…

3 weeks ago
Arkade Developers Supports 263 Cancer Patients Through Care Per Sq Ft Initiative, Collects 122 Blood Units in Strong Partnership with Tata Memorial Hospital and Sajjan Jain TrustArkade Developers Supports 263 Cancer Patients Through Care Per Sq Ft Initiative, Collects 122 Blood Units in Strong Partnership with Tata Memorial Hospital and Sajjan Jain Trust

Arkade Developers Supports 263 Cancer Patients Through Care Per Sq Ft Initiative, Collects 122 Blood Units in Strong Partnership with Tata Memorial Hospital and Sajjan Jain Trust

MUMBAI, India, April 7, 2025 /PRNewswire/ -- Arkade Developers Limited, through its charitable arm, The Sajjan Jain Support Trust, continues…

1 month ago
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic ObesityRhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity

Company to host conference call on April 7 at 8 a.m. ET April 06, 2025 12:00 ET  | Source: Rhythm…

1 month ago
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosisInventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from…

1 month ago
Show more Posts